Cangene Corp (CNJ-T) Stock Predictions - Stockchase
WATCH LIST
11
Cangene Corp (CNJ-T)

ON STOCKCHASE SINCE Jan 2002

Acquired by Emergent BioSoutions (March 2014)

biotechnology/pharmaceutical

Cangene Corp

CNJ-T

6 watching          
Join the Discussion

Cangene Corp (CNJ-T) SAVE Dec, 31, 1969, 7:00 pm

0.00 0 (100%)

This company is not ACTIVE.

What the experts are saying about CNJ-T



  • All
  • Filtered
Signal Opinion Expert
DON'T BUY
Cangene Corp(CNJ-T) 

July 30, 2012

Great balance sheet but company is at the US government’s mercy.  Will make money but over a longer period of time.  He is not a big fan of this story because there are a lot better opportunities out there right now.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Great balance sheet but company is at the US government’s mercy.  Will make money but over a longer period of time.  He is not a big fan of this story because there are a lot better opportunities out there right now.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Imhof

Vice Presi, AGF Investments Inc...

Price Price
$1.420
Owned Owned
Unknown

PAST TOP PICK
Cangene Corp(CNJ-T) 

December 6, 2011

(Top Pick Nov 11/10, Down 42.22%) Revenues are down. Major positive is a new CEO with a good track record came on a while ago. This company could be sold in a take-over, perhaps.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(Top Pick Nov 11/10, Down 42.22%) Revenues are down. Major positive is a new CEO with a good track record came on a while ago. This company could be sold in a take-over, perhaps.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$1.820
Owned Owned
Yes

PAST TOP PICK
Cangene Corp(CNJ-T) 

November 3, 2011

(A Top Pick Nov 11/10. Down 51.45%.) Sold his personal holdings at $3.18. Recently have had some good news. The new CEO has a good track record and a lot of potential. Lots of cash and a good balance sheet but they don't have enough products to sell.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Nov 11/10. Down 51.45%.) Sold his personal holdings at $3.18. Recently have had some good news. The new CEO has a good track record and a lot of potential. Lots of cash and a good balance sheet but they don't have enough products to sell.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$1.830
Owned Owned
Yes

PAST TOP PICK
Cangene Corp(CNJ-T) 

October 4, 2011

(Top Pick Nov 11/10, Down 56.50%) He got out of it personally but fund has it. Heard quarterly numbers were going to be bad and didn’t see it turning around for quite a while. New CEO that came on in August has quite a track record.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(Top Pick Nov 11/10, Down 56.50%) He got out of it personally but fund has it. Heard quarterly numbers were going to be bad and didn’t see it turning around for quite a while. New CEO that came on in August has quite a track record.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$1.370
Owned Owned
Yes

WAIT
Cangene Corp(CNJ-T) 

July 15, 2011

On the buy list (his partner’s). The CEO was booted out a little while ago. Company had problems because of major product in the states. It is going to spread out revenues over time. Moves sales force in-house. Need economies of scale to boost the bottom line. He says he would wait for it to go a little higher.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
On the buy list (his partner’s). The CEO was booted out a little while ago. Company had problems because of major product in the states. It is going to spread out revenues over time. Moves sales force in-house. Need economies of scale to boost the bottom line. He says he would wait for it to go a little higher.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$1.570
Owned Owned
Unknown

HOLD
Cangene Corp(CNJ-T) 

May 31, 2011

Undergoing tremendous changes. Looking for new products. They are looking to make an acquisition to expand product line.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Undergoing tremendous changes. Looking for new products. They are looking to make an acquisition to expand product line.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$1.950
Owned Owned
Yes

BUY
Cangene Corp(CNJ-T) 

March 16, 2011

A Contrarian pick in the pharma sector. Did well post-911 when people were bulking up on certain drugs. Management was a little optimistic about how well they could replace those drugs in the pipeline. He would expect it to suddenly jump out of the box.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
A Contrarian pick in the pharma sector. Did well post-911 when people were bulking up on certain drugs. Management was a little optimistic about how well they could replace those drugs in the pipeline. He would expect it to suddenly jump out of the box.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ben Stadelmann

Vice Presi, Contra the Heard...

Price Price
$2.820
Owned Owned
Yes

DON'T BUY
Cangene Corp(CNJ-T) 

December 6, 2010

Would recommend that you stay away from this one because there is no predictability from year to year on their earnings.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Would recommend that you stay away from this one because there is no predictability from year to year on their earnings.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Donville

President , Donville Kent Asset ...

Price Price
$3.100
Owned Owned
No

TOP PICK
Cangene Corp(CNJ-T) 

November 11, 2010

Some risks as revenues have gone down year to year from $240 million to $160 million. Marginal in terms of profitability from $60 million to $8 million. Has been profitable for most of the past 8 years. Good management and no debt and over $40 million in cash.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Some risks as revenues have gone down year to year from $240 million to $160 million. Marginal in terms of profitability from $60 million to $8 million. Has been profitable for most of the past 8 years. Good management and no debt and over $40 million in cash.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$3.150
Owned Owned
Yes

HOLD
Cangene Corp(CNJ-T) 

February 21, 2006

Past pick. 13% increase... doing well. Be content to hold.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Past pick. 13% increase... doing well. Be content to hold.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Higgins,

Vice Presi, Sentry Select Capita...

Price Price
$8.500
Owned Owned
Yes

TOP PICK
Cangene Corp(CNJ-T) 

January 24, 2002

Good earnings/revenues.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Good earnings/revenues.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Brendan Kyne

Chairman a, Leeward Hedge Funds ...

Price Price
$9.700
Owned Owned
Unknown

Showing 1 to 11 of 11 entries
Successfully Saved Company
Successfully Saved Company